A new study reveals that taking tirzepatide once a week can lead to significant and long-lasting weight loss for up to three ...

Taking tirzepatide drug once a week may produce clinically meaningful and sustained weight loss for at least 3 years in ad ...

(RTTNews) - Palatin Technologies Inc. (PTN) announced that its BMT-801 Phase 2 obesity co-administration ... a four-week treatment with tirzepatide alone (2.5 mg weekly) to confirm eligibility.

Patients with type 2 diabetes who switched to tirzepatide rather than escalating their dulaglutide dosage had greater weight ...

Diabetes patients on dulaglutide (Trulicity) had better glycemic control and more weight loss if they switched to tirzepatide ...

Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on ...

Physicians are turning to other options, including older, cheaper medications, as compounding GLP-1s comes to an end.

Researchers have found in a new research that among patients with poorly controlled type 2 diabetes, switching from ...

As obesity rates rise among individuals with T1D, GLP-1 agonist medications, indicated for T2D and weight loss, are ...

Phase 1 SAD/MAD studies to include hypothalamic ... co-administration of MC4R bremelanotide (1.25 mg daily) and GLP-1/GIP tirzepatide (2.5 mg weekly), tirzepatide alone (2.5 mg weekly ...

In the study, patients first received a four-week treatment with tirzepatide alone (2.5 mg weekly) to confirm eligibility. They were then randomly assigned to one of four treatment groups for an ...